摘要
目的评价抗癌平丸联合肝动脉栓塞化疗术(TACE)在中晚期肝癌患者中的临床疗效。方法肝癌患者按住院先后随机分为(1)治疗组30例:TACE术后第3天加抗癌平丸1.0g口服,3次/天,总量60g;(2)对照组30例:采用单纯TACE治疗。两组均以30～40d为1个周期,每例至少化疗2个周期。结果治疗组总有效率66.67%,生活质量改善率73.33%,中位生存期11.6个月。对照组总有效率56.67%,生活质量改善率53.33%,中位生存期8.5个月,两组比较,差异有统计学意义(P<0.05)。结论抗癌平丸联合TACE对中晚期肝癌患者是一种安全、有效的治疗方法。
Objective To evaluate the clinical effect of combining Kangaiping Pills with transcatheter arterial chemoembolization （TACE） in the patients with advanced liver cancer. Methods 60 patients with advanced liver cancer were divided into two groups. Therapy group（n=30） began to receive Kangaiping Pills（1 g,t. i. d. ,to total dose 60 g） for 3d after TACE. Control group（n=30） received the treatment of TACE only. The therapeutic cycle was repeated every 30- 40d and all the patients received at least two cycles. Results The overall effective rate and the life quality improvement rate were 66. 67% and 73. 33% in therapy group 56.67% and 53.33% in control group respectively. While the median survival time was 11.6 months in therapy group and 8.5 months in control group respectively. The diference of the two groups was significant （P〈0.05）. Conclusion Combining Kangaiping Pills with TACE may be a safe and effective therapy in the treatment of advanced liver cancer.
出处
《重庆医学》
CAS
CSCD
北大核心
2010年第5期563-564,共2页
Chongqing medicine
关键词
抗癌平丸
TACE
原发性肝癌
kangaipingwan
transcatheter arterial chemoembolization
primary hepatocellular carcinoma
